Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on August 14, 2017. The registrant is an emerging growth company incorporated in Nevada. The filing reports the commencement of a previously announced rights offering.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the mechanics of a capital raise event.
Material Changes and Events
- Rights Offering Commencement: On August 14, 2017, the Company commenced a rights offering.
- Subscription Terms: Each holder of Common Shares and certain Warrants as of the August 10, 2017 record date received one non-transferable Subscription Right for every share owned.
- Exercise Ratio and Price: Each Subscription Right entitles the holder to purchase 1.1608 Common Shares at a subscription price of $1.00 per share.
- Documentation: The Company began mailing prospectus supplements and ancillary documents to eligible holders on the commencement date.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary regarding future performance. It notes that a legal opinion from Nutter McClennen & Fish LLP regarding the validity of the Subscription Rights and issuable shares was delivered and filed as an exhibit. The filing incorporates a press release dated August 14, 2017, by reference.
Investor Verification Checklist
- Verify the total number of shares outstanding as of the August 10, 2017 record date to calculate potential dilution.
- Confirm the subscription deadline and the specific terms for exercising the rights (e.g., cashless exercise options).
- Review the full prospectus supplement (Exhibit 99.1 and related documents) for underwriting arrangements and use of proceeds.
- Check the Company's recent 10-Q or 10-K filings for the most recent liquidity position and cash burn rate, as this 8-K does not provide them.